Select Publications
Vaxiion's 2025 publication in Molecular Cancer Therapeutics
Key highlights:
- VAX014 co-stimulates the STING and RIG-I pathways as part of its mechanism of action
- VAX014 has optimal antitumor activity in tumors expressing STING and/or RIG-I, differentiating VAX014 from oncolytic viruses
- Elevated expression of STING and/or RIG-I and Type-I IFN associated with better clinical outcome
Select Publications
Vaxiion's 2023 publication in The Journal for ImmunoTherapy of Cancer
Key highlights:
- VAX014 elicits tumor-specific T cell-mediated immune clearance of injected and in non-injected tumors
- VAX014 activates multiple innate immune pathways leading to T cell priming
- Strong synergy with systemic immune checkpoint blockade
Vaxiion's 2022 publication in Cancer Immunology Research
Key highlights:
- VAX014 elicits tumor-specific T cell-mediated immune clearance of orthotopic bladder tumors
- VAX014 acts through in situ immunization
- Strong synergy with systemic PD-(L)1 systemic immune checkpoint blockade
Vaxiion's 2016 publication in Molecular Therapy - Oncolytics
Key highlights:
- First publication characterizing details of the structure, integrin-specificity, and oncolytic mechanism of action of VAX014 (preclincial name VAX-IP)
- Preliminary efficacy data in two murine models of non-muscle invasive bladder cancer
- Established dose level(s) and dosing frequency